500 patients67,039 observations150 daysLIVE

Patient P-03183

Synthetic patientONX-7 · Day 140 · 45–54 · M · baseline S03Open companion preview
Therapy response
Declining
Tolerance
Improving
GI state
Unstable
Inflammatory state
Unstable
Nutritional resilience
Unstable
Discontinuation risk
64%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events
solid = observed · dashed = predicted
  1. Day 0 ONX-7 startedBaseline state S03
  2. Day 96 Trajectory diverged from predictionObserved response fell below the model's expected path.

What changed?

Trajectory began diverging from predicted response on Day 96.

Primary contributors, last 14 days
  • Toxicity-8
  • Inflammatory activity+5
  • Treatment adherence-5
  • GI instability+4

What helped?

No interventions yet.

    LIFE OS recommendation
    GI Support Protocol GI-04
    60%
    probability of meaningful tolerance improvement
    • 284 similar trajectories
    • 82% showed improvement
    • median effect visible after 8 days

    Biological layers

    Which pathways look influenced, and by which layer of this person's biology.

    Pathways under pressure
    • Mucosal barrier integrity 90
      • DNAFUT2 non-secretor lowers mucosal fucosylation
      • MicrobiomeAkkermansia low → thinner mucus layer
      • Daily logGI symptom score 73 and rising
      • WearableSleep 5.3 h, below personal baseline
    • Butyrate / short-chain fatty acid production 55
      • MicrobiomeButyrate capacity 37/100
      • Daily logFibre intake low in recent food logs
    • Autonomic recovery 45
      • WearableResting HR 77 bpm
      • WearableShort sleep window
    • Inflammatory signalling 40
      • BloodInflammatory load index 62
      • WearableHRV 32 ms, trending down
    • Drug metabolism and exposure 40
      • DNACYP2D6 poor metabolizer → higher exposure
    DNA
    Fictional pharmacogenomic panel
    • FUT2 rs601338 AA (non-secretor)
      Reduced mucosal fucosylation
    • CYP2D6 Poor metabolizer
      Higher exposure at standard dose
    Microbiome
    Shannon diversity 2.6 · butyrate capacity 37/100
    • Akkermansia muciniphilaLow
    • Faecalibacterium prausnitziiNormal
    • Bacteroides fragilisNormal
    • Bifidobacterium longumLow
    • EnterobacteriaceaeNormal
    Wearable, last 14 days
    daily evolution fed into the runtime
    HRV
    30 ms
    Sleep
    5.1 h
    Steps
    5,583
    Resting HR
    79 bpm
    Daily log: GI score 73, nutritional resilience 37, adherence 64.

    What this patient sees in NostraAI

    The content that steers the trajectory: what to eat, what to do, what to take.

    Open companion preview
    What to eat
    • Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
    • Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
    • Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
    • Avoid known triggers for now: fried or oily food, dairy, alcohol
    What to do
    • Track each bowel movement today: time, stool form, urgency, overnight waking
    • Keep the current walking rhythm
    • Protect a 7.5-hour sleep window; screens off 30 minutes before
    • Keep hydration steady: small amounts through the day rather than large volumes at once
    What to take
    • Take the scheduled dose as agreed with your care team
    • Electrolyte solution, one sachet after any loose stool
    • Fictional demo item: oral nutrition supplement with lunch

    284 biologically similar trajectories

    Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

    PatientSimilarityBaselineInterventionOutcomeResponse today
    P-0328049%S1357
    P-0306546%S1659
    P-0338444%S0155
    P-0309943%S17CR-01improved55
    P-0315141%S1851
    P-0300440%S0356
    P-0308040%S0962
    P-0319140%S19GI-04improved51
    P-0322540%S19GI-04improved50
    P-0344440%S1762
    P-0326039%S1954
    P-0316638%S20CR-01improved62